Hormonal
The effect of Tirzepatide on Fat-Free Mass (FFM) is inconclusive and uncertain, with evidence showing significant FFM loss that may be greater than or comparable to other anti-obesity drugs depending on the dose and study.
Current research does not provide a clear answer on whether Tirzepatide preserves muscle mass better than other weight loss strategies. Some studies indicate significant muscle loss occurs alongside fat loss, while others suggest it might be less severe than with other drugs. More research is needed to determine if specific dosing protects lean mass.
Finally, the effect of TZP on fat-free mass (FFM) is still uncertain because the findings remain inconclusive.
Why this rating
Based on small sample sizes and heterogeneous assessment methods (BIA vs DXA) in the included RCTs.
Source
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Vincenzo Rochira et al. · Diseases · 2024
DOI 10.3390/diseases12090204
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →